California Public Employees Retirement System Has $17.40 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

California Public Employees Retirement System lessened its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 4.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 143,129 shares of the biotechnology company’s stock after selling 7,391 shares during the quarter. California Public Employees Retirement System owned approximately 0.15% of Sarepta Therapeutics worth $17,403,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Norges Bank acquired a new stake in shares of Sarepta Therapeutics during the 4th quarter worth about $126,315,000. Wellington Management Group LLP lifted its position in Sarepta Therapeutics by 32.3% during the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock worth $340,527,000 after acquiring an additional 665,087 shares during the last quarter. Soros Fund Management LLC bought a new stake in shares of Sarepta Therapeutics during the third quarter worth approximately $25,800,000. Swedbank AB bought a new position in shares of Sarepta Therapeutics during the fourth quarter worth approximately $16,706,000. Finally, Vanguard Group Inc. lifted its holdings in Sarepta Therapeutics by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company’s stock worth $1,104,701,000 after purchasing an additional 117,904 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Trading Down 7.1 %

Shares of SRPT stock opened at $54.43 on Friday. Sarepta Therapeutics, Inc. has a 1-year low of $54.26 and a 1-year high of $173.25. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock has a market cap of $5.28 billion, a price-to-earnings ratio of 43.54 and a beta of 0.79. The stock has a 50-day moving average of $96.95 and a 200-day moving average of $113.78.

Analysts Set New Price Targets

SRPT has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a research report on Wednesday, March 19th. Royal Bank of Canada downgraded shares of Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price target for the company from $161.00 to $87.00 in a research report on Monday, March 31st. Needham & Company LLC reduced their price target on Sarepta Therapeutics from $202.00 to $183.00 and set a “buy” rating on the stock in a research report on Thursday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $163.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Finally, Scotiabank decreased their price target on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating on the stock in a research report on Thursday, March 20th. Six research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $163.18.

Insiders Place Their Bets

In other news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares in the company, valued at $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 7.70% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.